Phoslyra

Phoslyra Uses, Dosage, Side Effects, Food Interaction and all others data.

Phoslyra when taken with meals, combines with dietary phosphate to form insoluble Calcium Phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Phoslyra is highly soluble at neutral pH, making the Calcium readily available for binding to phosphate in the proximal small intestine. Orally administered Phoslyra from pharmaceutical dosage forms has been demonstrated to be systemically absorbed up to approximately 40% under fasting conditions and up to approximately 30% under non fasting conditions. This range represents data from both healthy subjects and renal dialysis patients under various conditions.

Patients with advanced renal insufficiency (creatinine clearance less than 30 ml/min) exhibit phosphate retention and some degree of hyperphosphatemia. The retention of phosphate plays a pivotal role in causing secondary hyperparathyroidism associated with osteodystrophy, and soft-tissue calcification. The mechanism by which phosphate retention leads to hyperparathyroidism is not clearly delineated. Therapeutic efforts directed toward the control of hyperphosphatemia include reduction in the dietary intake of phosphate, inhibition of absorption of phosphate in the intestine with phosphate binders, and removal of phosphate from the body by more efficient methods of dialysis. The rate of removal of phosphate by dietary manipulation or by dialysis is insufficient. Dialysis patients absorb 40% to 80% of dietary phosphorus. Therefore, the fraction of dietary phosphate absorbed from the diet needs to be reduced by using phosphate binders in most renal failure patients on maintenance dialysis. Calcium acetate when taken with meals combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces. Maintenance of serum phosphorus below 6.0 mg/dl is generally considered as a clinically acceptable outcome of treatment with phosphate binders. Calcium acetate is highly soluble at neutral pH, making the calcium readily available for binding to phosphate in the proximal small intestine.

Trade Name Phoslyra
Generic Calcium Acetate
Calcium Acetate Other Names Acetate of lime, Brown acetate of lime, Calcio acetato, Calcium acetate, calcium ethanoate, Gray acetate of lime, Lime acetate, Lime pyrolignite
Weight 667mg, 667mg/5ml,
Type Oral capsule, oral liquid, oral tablet
Formula C4H6CaO4
Weight Average: 158.166
Monoisotopic: 157.989199835
Groups Approved, Investigational
Therapeutic Class Drugs for reduction of serum phosphorus in patients with ESRD, Minerals in bone formation, Specific mineral preparations
Manufacturer
Available Country United States,
Last Updated: September 19, 2023 at 7:00 am
Phoslyra
Phoslyra

Uses

Phoslyra is used for the treatment of hyperphosphatemia, control of hyperphosphatemia in end stage renal failure.

Phoslyra is also used to associated treatment for these conditions: Hyperphosphataemia, High phosphate levels, Astringent, Prophylaxis of bacterial skin infections

How Phoslyra works

Calcium acetate and other calcium salts are phosphate binders. They work by binding with the phosphate in the food you eat, so that it is eliminated from the body without being absorbed.

Dosage

Phoslyra dosage

Adult:Initially 3-4 g daily. Usual range: 6-12 g daily.

To control hyperphosphataemia in chronic renal failure: Initially 1.334 g (338 mg of calcium). May increase dosage gradually according to serum phosphate conc, provided hypercalcaemia does not occur.

Side Effects

In clinical studies, patients have occasionally experienced nausea during Phoslyra therapy. Hypercalcemia may occur during treatment with Phoslyra. Mild hypercalcemia (Ca > 10.5 mg/dl) may be asymptomatic or manifest itself as constipation, anorexia, nausea and vomiting. More severe hypercalcemia (Ca>12mg/dl) is associated with confusion, delirium, stupor and coma. The long-term effect of Phoslyra on the progression of vascular or soft-tissue calcification has not been determined. Isolated cases of pruritus have been reported which may represent allergic reactions.

Toxicity

Oral, rat: LD50 = 4280 mg/kg. Symptoms of overdose include mild hypercalcemia (constipation; loss of appetite; nausea and vomiting), and severe hypercalcemia (confusion; full or partial loss of consciousness; incoherent speech).

Precaution

Patients with end stage renal failure may develop hypercalcemia when given calcium with meals. No other calcium supplements should be given concurrently with Phoslyra.

Interaction

Phoslyra may decrease the bioavailability of tetracycline.

Food Interaction

  • Take with food. When taken with food, calcium acetate forms an insoluble complex with the phosphorus from food, reducing phosphorus serum concentrations.

Elimination Route

40% is absorbed in the fasting state and approximately 30% is absorbed in the nonfasting state following oral administration.

Elimination Route

Calcium acetate when taken with meals, combines with dietary phosphate to form insoluble calcium phosphate which is excreted in the feces.

Pregnancy & Breastfeeding use

Animal reproduction studies have not been conducted with Phoslyra. It is not known whether Phoslyra can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Phoslyra should be given to a pregnant woman only if clearly needed.

There are no adequate studies in women for determining infant risk when using the medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

Contraindication

Phoslyra is contraindicated in patients with hypercalcemia.

Acute Overdose

Administration of Phoslyra in excess of the appropriate daily dosage can cause severe hypercalcemia.

Storage Condition

Store in a cool & dry place at room temperature. Protect from light, heat & moisture.

Innovators Monograph

You find simplified version here Phoslyra

Phoslyra contains Calcium Acetate see full prescribing information from innovator Phoslyra Monograph, Phoslyra MSDS, Phoslyra FDA label

*** Taking medicines without doctor's advice can cause long-term problems.
Share